TTD Drug ID: DNCL002613

Drug Information
Name	Brivanib
Company	Bristol-Myers Squibb
Indication	First-line liver cancer, liver cancer (TACE) (see also colorectal, sarcoma) [ICD9: 140-229, 155   ICD10: C00-C96, C22.0]			Phase III
	Metastatic colorectal cancer [ICD9: 153, 154   ICD10: C18-C21]			Phase II
	Sarcoma			Phase II
Structure	Click to save drug structure in 3D MOL format Click to save drug structure in 2D MOL format
InChI	1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3) 16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11 -/m1/s1
InChIKey	WCWUXEGQKLTGDX-LLVKDONJSA-N
Canonical SMILES	CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C
Isomeric SMILES	CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C
Formula	C19H19FN4O3
PubChem Compound ID	CID 11234052.
Target	FGFR
	VEGFR

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.